Jazz Pharmaceuticals (NASDAQ:JAZZ) PT Raised to $179.00

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective lifted by Royal Bank of Canada from $175.00 to $179.00 in a research report sent to investors on Wednesday, Benzinga reports. They currently have an outperform rating on the specialty pharmaceutical company’s stock.

A number of other equities analysts have also issued reports on the stock. Wells Fargo & Company reduced their target price on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 1st. UBS Group dropped their price target on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating for the company in a research note on Tuesday, July 2nd. Robert W. Baird dropped their price target on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating for the company in a research note on Thursday, August 1st. Piper Sandler dropped their price target on shares of Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating for the company in a research note on Thursday, August 1st. Finally, StockNews.com raised shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $173.43.

Jazz Pharmaceuticals Price Performance

NASDAQ:JAZZ opened at $111.13 on Wednesday. The firm has a market cap of $7.01 billion, a PE ratio of 22.91, a price-to-earnings-growth ratio of 1.34 and a beta of 0.57. Jazz Pharmaceuticals has a 12 month low of $99.06 and a 12 month high of $134.48. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. The company’s 50-day moving average price is $111.05 and its two-hundred day moving average price is $109.66.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 EPS for the quarter, beating analysts’ consensus estimates of $3.80 by $0.87. Jazz Pharmaceuticals had a net margin of 10.10% and a return on equity of 28.65%. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. On average, equities analysts anticipate that Jazz Pharmaceuticals will post 16.03 EPS for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the transaction, the senior vice president now owns 14,531 shares in the company, valued at $1,573,707.30. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in JAZZ. Capital World Investors acquired a new position in shares of Jazz Pharmaceuticals in the first quarter valued at approximately $171,943,000. Swedbank AB acquired a new position in Jazz Pharmaceuticals during the second quarter worth $106,936,000. Rubric Capital Management LP acquired a new position in Jazz Pharmaceuticals during the second quarter worth $65,812,000. Pacer Advisors Inc. lifted its stake in Jazz Pharmaceuticals by 40.7% in the second quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company’s stock valued at $194,346,000 after acquiring an additional 527,187 shares during the last quarter. Finally, Baupost Group LLC MA lifted its stake in Jazz Pharmaceuticals by 52.8% in the second quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock valued at $136,000,000 after acquiring an additional 440,552 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.